<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589728</url>
  </required_header>
  <id_info>
    <org_study_id>AML2320</org_study_id>
    <nct_id>NCT04589728</nct_id>
  </id_info>
  <brief_title>Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96</brief_title>
  <official_title>Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit Patients With Acute Myeloid Leukemia Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an retrospective and prospective observational multinstitutional study to evaluate&#xD;
      the impact on outcome of the combination of HMA plus venetoclax in AML patients unfit for&#xD;
      intensive chemotherapy in a &quot;real-life&quot; scenario. No additional procedures or visits other&#xD;
      than those required by normal clinical practice will be required. Patients will be observed&#xD;
      for at least 24 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an retrospective and prospective observational multinstitutional study to evaluate&#xD;
      the impact on outcome of the combination of HMA plus venetoclax in patients with AML unfit&#xD;
      for intensive chemotherapy in a &quot;real-life&quot; scenario. At least 104 AML adult patients&#xD;
      ineligible for intensive chemotherapy treated with the combination HMA plus venetoclax under&#xD;
      the Italian Law No.648/96 by December 2021 will be enrolled. No additional procedures or&#xD;
      visits other than those required by normal clinical practice will be required. Patients will&#xD;
      be observed for at least 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>15 months</time_frame>
    <description>Evaluation of Overall Survival in AML patients ineligible for intensive chemotherapy treated with the combination of HMA plus Venetoclax</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>All patients being observed during the study duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax plus HMA</intervention_name>
    <description>patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with a diagnosis of AML ineligible for intensive chemotherapy treated with the&#xD;
        combination HMA plus venetoclax under the Italian Law No.648/96 by December 2021.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 18 years with a diagnosis of previously untreated primary or secondary&#xD;
             AML;&#xD;
&#xD;
          -  Deemed ineligible for intensive chemotherapy because of age (≥75 years), performance&#xD;
             status or comorbidities as defined by the treating physicians, according to&#xD;
             SIE/SIES/GITMO criteria;&#xD;
&#xD;
          -  Eligible to receive the combination HMA plus venetoclax under the Italian Law&#xD;
             No.648/96 by December 2021;&#xD;
&#xD;
          -  Signed written informed consent according to ICH/EU/GCP and national local laws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic Leukemia;&#xD;
&#xD;
          -  Previous first-line treatments for AML;&#xD;
&#xD;
          -  Previous treatments with HMA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro S Rambaldi</last_name>
      <email>arambaldi@asst-pg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio U Curti</last_name>
      <email>antonio.curti2@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asst Degli Spedali Civili Di Brescia - Uo Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika U Borlenghi</last_name>
      <phone>3402526539</phone>
      <email>erika.borlenghi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Careggi - Firenze - Sod Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo Gianfaldoni</last_name>
      <email>ggianfaldoni@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti - Foggia - Uoc Ematologia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celestino U Ferradina</last_name>
      <email>ferrandina10@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
      <phone>3388178577</phone>
      <email>direnzo.ematolecce@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato U Bassan</last_name>
      <email>Renato.Bassan@aulss3.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Cairoli</last_name>
      <phone>3478939057</phone>
      <email>roberto.cairoli@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola P Fracchiolla</last_name>
      <email>ns.fracchiolla@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Todisco</last_name>
      <email>Elisabetta.Todisco@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela E Cilloni</last_name>
      <phone>3332818086</phone>
      <email>daniela.cilloni@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Salerno, Presidio Ospedaliero Tortora Pagani - Ematologia</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
      <email>c.califano@aslsalerno.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonino C Mulè</last_name>
      <email>a.mule@villasofia.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Paola M Martelli</last_name>
      <email>mpmartelli@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prassede Salutari</last_name>
      <phone>3398073869</phone>
      <email>prassede.salutari@ausl.pe.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ao Regionale S. Carlo - Potenza - Sic Ematologia</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Pizzuti</last_name>
      <email>pizzuti.m@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Policlinico Tor Vergata - Roma - Uoc Trapianto Cellule Staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriano C Venditti</last_name>
      <email>adriano.venditti@uniroma2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou &quot;San Giovanni Di Dio E Ruggi D'Aragona&quot; - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmine S Salleri</last_name>
      <email>cselleri@unisa.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Di Sassari - Cliniche Universitarie - Stabilimento Cliniche Di San Pietro - Uoc Ematologia</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio U Fozza</last_name>
      <phone>3397560639</phone>
      <email>cfozza@uniss.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Sassuolo Spa - Ematologia</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Bigliardi</last_name>
      <email>s.bigliardi@ausl.mo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Senese - Uoc Ematologia E Trapianti</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica E Bocchia</last_name>
      <email>bocchia@unisi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesta E Audisio</last_name>
      <email>eaudisio@cittadellasalute.to.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Di Viterbo, Complesso Ospedaliero Di Belcolle - Uoc Ematologia</name>
      <address>
        <city>Viterbo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ambra Di Veroli</last_name>
      <email>ambra.diveroli@asl.vt.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venetoclax</keyword>
  <keyword>unfit AML patients</keyword>
  <keyword>Hypomethylating agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

